Watch Walgreens, Nike, Palantir, and PDD
Walgreens (WBA) is looking more like a “buyout” pump and “sell the rumor” dump. The drugstore stock gained 6.5% to close at $10.82 after reports surfaced that private equity firm Sycamore Partners is securing $10 billion in funding from Morgan Stanley (MS) and UBS.Shareholders will likely reject a lowball bid but may not have a choice. The “takeunder” is the only bid that Walgreens might receive.A mild sell-off in artificial intelligence-related suppliers left Palantir (PLTR) down by 10.53% on Monday. PLTR stock peaked at over $120 just a few days ago. Sentiment rapidly reversed, as markets speculated that CEO Karp sold shares. Still, bears do not hold a big short position on the stock. The short float is 3.33%.China’s PDD (PDD), which owns Temu, suddenly reversed after the stock rallied from around $95 last month to above $130. Anyone who chased the rally in Chinese technology stocks may face losses from here. Only investors who bought shares of Alibaba (BABA), Bilibili (BILI), or JD (JD) at the lows in Q4/2024 are fine.China cannot predict if the U.S. will soften its stance on trade or abruptly change directions. Stock markets are pricing in for the latter scenario. The U.S. President reiterated plans to impose 25% tariffs against Mexico and Canada on March 1, 2025.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


